期刊文献+

非小细胞肺癌术前辅助化疗疗效观察 被引量:2

原文传递
导出
摘要 目的:探讨分析非小细胞肺癌术前辅助化疗的疗效。方法:选取非小细胞肺癌患者70例,在征求患者家属同意的情况下分为观察组和对照组,每组患者各35例。观察组术前进行辅助化疗后进行手术,对照组直接进行手术。比较两组患者的疗效。结果:观察组辅助化疗有效率为51.4%。观察组患者手术的切除率为85.7%,对照组患者手术的切除率为71.4%。对患者术后1年和术后3年生存率进行跟踪记录,观察组患者术后1年存活率为74.3%,术后3年存活率为37.1%.对照组患者术后1年存活率为62.9%,术后3年存活率为28.6%。两组在手术切除率、术后1年存活率、术后3年存活率方面比较有显著差异(P<0.05)。两组均无不良事故(术中死亡、手术并发症)发生,两组在不良事故发生情况比较,P>0.05,无显著性差异。结论:非小细胞肺癌术前辅助化疗疗效显著,能够提高手术切除率和术后存活率,值得临床推广。
作者 李放
机构地区 辽河油田总医院
出处 《亚太传统医药》 2013年第2期116-117,共2页 Asia-Pacific Traditional Medicine
  • 相关文献

参考文献5

二级参考文献35

  • 1支修益,刘宝东,许庆生,张毅,苏雷,王辉荣,胡牧.CT和正电子发射计算机断层摄影显像对确定非小细胞肺癌纵隔淋巴结转移的临床价值[J].中华医学杂志,2005,85(29):2026-2029. 被引量:15
  • 2Novoa N,Varela G,Jimenez MF.Morbidity after surgery for non-small cell lung carcinoma is not related to neoadjuvant chemotherapy.Eur J Cardiothorac Surg,2001,20:700-704.
  • 3Jocelyne M,Robert JG,Amir A,et al.Morbidity and mortality after neoadjuvant therapy for lung cancer:the risks of right pneumonectomy.Ann Thorac Surg,2001,72:1149-1154.
  • 4Christophe D,Pascal T,Xavier T,et al.Postoperative complications in relation with induction therapy for lung cancer.Eur J Cardiothorac Surg,2001,20:385-390.
  • 5Luca V,Luca L,Claudia G,et al.Results of induction chemotherapy followed by surgical resection in patients with stage ⅢA(N2) non-small cell lung cancer:the importance of the nodal down-staging after chemotherapy.Eur J Cardiothorac Surg,2001,20:1106-1112.
  • 6[1]De Pierre A. Overview of the role for neoadjuvant therapy for early-stage non-small cell lung cancer. Lung Cancer,2000,29(Suppl 2)∶124-125.
  • 7[2]Albain KS, Pass HI. Induction therapy before surgery for non-small cell lung cancer. Lung Cancer,2000,29(Suppl 2)∶168-171.
  • 8[3]De Pierre A, Milleron B, Chevret S, et al. French phase Ⅲ trial of preoperative chemotherapy (PCT) in resectable stage Ⅰ (except T1N0), Ⅱ, Ⅲa non-small cell lung cancer (NSCLC). Lung Cancer,2000,29(Suppl 1)∶91.
  • 9[4]Splinter T, Groen H, Smit E, et al. Randomized multicenter phase Ⅱ study of chemotherapy followed by surgery versus surgery alone in stage Ⅰand Ⅱ non-small cell lung cancer (NSCLC). Lung Cancer,2000,29(Suppl 1)∶90.
  • 10[5]Eberhardt W, Korfee S, Wagner H, et al. "Minimal N2-disease”(operable) stage ⅢA non-small cell lung cancer: Prospectively randomized multicenter German phase-Ⅲ-trial of surgery (S) followed by adjuvant radiotherapy (RTx) versus "Trimodality treatment”-Early results of feasibility and toxicity in this setting. Lung Cancer,2000,29(Suppl 1)∶95-96.

共引文献55

同被引文献42

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部